Drug Trial Radar · NCT05445154
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Last checked: Nov 19, 2026Latest source record: Jul 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
58
Planned (sponsor's estimate)
Start
Aug 31, 2021
Primary completion
Oct 31, 2024
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 59 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to describe the dose limiting toxicities (DLT) of SKLB1028 when combined with cytarabine/ daunorubicin remission induction in a 7+3 schedule. Safety and tolerability of SKLB1028 will also be evaluated. This study will also characterize the pharmacokinetics (PK) of SKLB1028 when given in combination with cytarabine/daunorubicin remission induction and high-dose cytarabine (HiDAC) consolidation therapy in newly diagnosed acute myeloid leukemia .
Conditions
- Newly Diagnosed Acute Myeloid Leukemia (AML)
Interventions
SKLB1028 Dose EscalationDrug
Drug :SKLB1028 ;Drug: Cytarabine ;Drug: Daunorubicin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicities (DLTs)Time frame: up to Day42
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.